当前位置: 首页 >> 检索结果
共有 62504 条符合本次的查询结果, 用时 5.3475459 秒

1241. Correction to: Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.

来源: Circulation. 2025年151卷3期e29页

1242. Correction to: Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.

来源: Circulation. 2025年151卷3期e30页

1243. An Advocacy Agenda for the Human Brain: Moving From Brain Health to Brain Capital.

作者: Mitchell S V Elkind.;Harris Eyre.;Cheryl Pegus.
来源: Circulation. 2025年151卷3期e24-e26页

1244. AL or ATTR Amyloidosis? Never Two Without Three.

作者: Mario Nuvolone.;Giuseppe D Sanna.;Giovanni Palladini.
来源: Circulation. 2025年151卷3期274-281页

1245. Response by Park and Kang to Letter Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".

作者: Sung-Ji Park.;Duk-Hyun Kang.
来源: Circulation. 2025年151卷3期e28页

1246. Survivorship After Cardiogenic Shock.

作者: Eric J Hall.;Sachin Agarwal.;C Munro Cullum.;Shashank S Sinha.;E Wesley Ely.;Maryjane A Farr.
来源: Circulation. 2025年151卷3期257-271页
Advances in critical care therapies for patients with cardiogenic shock (CS), including temporary mechanical circulatory support and multidisciplinary shock teams, have led to improved survival to hospital discharge, ranging from 60% to 70%. After their index hospitalization, however, survivors of CS may continue to face cardiac as well as extracardiac sequelae of these therapies and complications for years to come. Most studies in CS have focused primarily on survival, with limited data on long-term recovery measures among survivors. In other forms of critical illness, research indicates that many intensive care unit survivors experience impairments in multiple domains, such as cognitive function, physical ability, and mental health. These impairments, collectively referred to as Post-Intensive Care Syndrome, in turn impact survivors' quality of life and future prognosis. This review identifies unique aspects of CS-related survivorship, highlights lessons learned from other forms of critical illness, and outlines future research directions to determine specific strategies to enhance recovery and survivorship after CS.

1247. SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap.

作者: Ify R Mordi.;Rory J McCrimmon.;Chim C Lang.
来源: Circulation. 2025年151卷3期199-201页

1248. ADMET-AI Enables Interpretable Predictions of Drug-Induced Cardiotoxicity.

作者: Souhrid Mukherjee.;Kyle Swanson.;Parker Walther.;Rabindra V Shivnaraine.;Jeremy Leitz.;Paul D Pang.;James Zou.;Joseph C Wu.
来源: Circulation. 2025年151卷3期285-287页

1249. Letter by Wang and Peng Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".

作者: Junwen Wang.;Yong Peng.
来源: Circulation. 2025年151卷3期e27页

1250. Driving Restrictions and Incapacitation Vulnerability Evaluation After ST-Segment-Elevation Myocardial Infarction: DRIVE-STEMI Study.

作者: Zachary Singer.;Harindra C Wijeysundera.;Feng Qiu.;Jiming Fang.;Ragavie Manoragavan.;Christopher S Simpson.;Luiz F Ybarra.
来源: Circulation. 2025年151卷3期282-284页

1251. Correction to: Contributors to the Growth of Same Day Discharge After Elective Percutaneous Coronary Intervention.

来源: Circ Cardiovasc Interv. 2025年18卷1期e000095页

1252. Comparative Outcomes of Transcatheter Edge-to-Edge Repair and Tricuspid Valve Surgery for Isolated Tricuspid Valve Regurgitation.

作者: Conor M Lane.;Mackram F Eleid.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014991页

1253. Door to Pulmonary Artery Perfusion: Are We Ready for a New Time-Based Metric?

作者: Sanjum S Sethi.;Mehdi H Shishehbor.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014990页

1254. Outcomes of Intracoronary Imaging-Guided PCI With Optimal Versus Suboptimal Results: A Meta-Analysis.

作者: Mohamed Hamed.;Sheref A Mohamed.;Asmaa Ahmed.;Muhammad Adnan Haider.;El-Moatasem Gabr.;Dharam J Kumbhani.;Anthony Bavry.;Emmanouil S Brilakis.;Mamas A Mamas.;Ayman Elbadawi.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014681页

1255. Use of Claims to Assess Outcomes and Treatment Effects in the Evolut Low Risk Trial.

作者: Neel M Butala.;Christina Lalani.;Archana Tale.;Yang Song.;Dhaval Kolte.;Suzanne Baron.;Jordan Strom.;David J Cohen.;Robert W Yeh.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014592页
Food and Drug Administration-mandated postmarket studies for transcatheter aortic valve replacement in low-risk populations plan to use passively collected registry data linked to claims for long-term follow-up out to 10 years. Therefore, it is critically important to understand the validity of these claims-based end points. We sought to evaluate the ability of administrative claims with International Classification of Diseases-Tenth Revision (ICD-10) codes to identify trial-adjudicated end points and reproduce treatment comparisons of aortic valve replacement in the Evolut Low Risk Trial.

1256. How Can We Optimize the Results of Coronary Bioresorbable Scaffolds?

作者: Fernando Alfonso.;Teresa Bastante.;Fernando Rivero.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014889页

1257. Optimal Predilatation Treatment Before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis: The OPTIMIS Trial.

作者: Kirstine Nørregaard Hansen.;Jens Trøan.;Akiko Maehara.;Manijeh Noori.;Mikkel Hougaard.;Julia Ellert-Gregersen.;Karsten Tange Veien.;Anders Junker.;Henrik Steen Hansen.;Jens Flensted Lassen.;Lisette Okkels Jensen.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014665页
Bioresorbable scaffolds (BRS) were developed to overcome limitations related to late stent failures of drug-eluting stents, but lumen reductions over time after implantation of BRS have been reported. This study aimed to investigate if lesion preparation with a scoring balloon compared with a standard noncompliant balloon minimizes lumen reduction after implantation of a Magmaris BRS assessed with optical coherence tomography and intravascular ultrasound.

1258. Impact of Time to Catheter-Based Therapy on Outcomes in Acute Pulmonary Embolism.

作者: Robert S Zhang.;Eugene Yuriditsky.;Peter Zhang.;Bedros Taslakian.;Lindsay Elbaum.;Allison A Greco.;Vikramjit Mukherjee.;Radu Postelnicu.;Nancy E Amoroso.;Thomas S Maldonado.;James M Horowitz.;Sripal Bangalore.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014499页
The aim of this study was to examine the impact of early versus delayed catheter-based therapies (CBTs) on clinical outcomes in patients with acute intermediate-risk pulmonary embolism (PE).

1259. Right Ventricular Function: Deep Learning's Prognostic Edge in Mitral Regurgitation.

作者: Vidhu Anand.;Vuyisile T Nkomo.
来源: Circ Cardiovasc Imaging. 2025年18卷1期e017788页

1260. Deep Learning-Enabled Assessment of Right Ventricular Function Improves Prognostication After Transcatheter Edge-to-Edge Repair for Mitral Regurgitation.

作者: Mark Lachmann.;Vera Fortmeier.;Lukas Stolz.;Márton Tokodi.;Attila Kovács.;Amelie Hesse.;Antonia Leipert.;Elena Rippen.;Héctor Alfonso Alvarez Covarrubias.;Moritz von Scheidt.;Jule Tervooren.;Ferdinand Roski.;Michelle Fett.;Muhammed Gerçek.;Tibor Schuster.;Gerhard Harmsen.;Shinsuke Yuasa.;N Patrick Mayr.;Adnan Kastrati.;Heribert Schunkert.;Michael Joner.;Erion Xhepa.;Karl-Ludwig Laugwitz.;Jörg Hausleiter.;Volker Rudolph.;Teresa Trenkwalder.
来源: Circ Cardiovasc Imaging. 2025年18卷1期e017005页
Right ventricular (RV) function has a well-established prognostic role in patients with severe mitral regurgitation (MR) undergoing transcatheter edge-to-edge repair (TEER) and is typically assessed using echocardiography-measured tricuspid annular plane systolic excursion. Recently, a deep learning model has been proposed that accurately predicts RV ejection fraction (RVEF) from 2-dimensional echocardiographic videos, with similar diagnostic accuracy as 3-dimensional imaging. This study aimed to evaluate the prognostic value of the deep learning-predicted RVEF values in patients with severe MR undergoing TEER.
共有 62504 条符合本次的查询结果, 用时 5.3475459 秒